















Volume/Tom 72; Number/Numer 4/2021
ISSN 0423–104X, e-ISSN 2299–8306
A 6-year-old boy was first investigated in our clinic for 
a decrease of height velocity from age 3 years; the GV was 
about 4.3 cm/year. He was the firstborn by vaginal deliv-
ery at term, after an uneventful pregnancy. Birth weight 
was 3400 g, birth length was 50.0 cm. The parents were 
not related and had a normal stature: 169.0 cm and 158.2 
cm, respectively, with no family history of similar disease. 
At admittance his height was 109.0 cm (1.91 SD) and his 
weight was 18.1 kg (–1.27 SD). There was no other special 
clinical phenotype. Laboratory tests did not show any 
abnormalities in thyroid hormone, cortisol, and adreno-
corticotrophic hormone. Hormone analysis revealed that 
the IGF-1 level was 102 ng/mL — the normal range at this 
age is 52–197 ng/mL. The growth hormone level reached 
normal values after exercise challenge test (17.53 ng/mL). 
BA was 5.4 years old; he was diagnosed as failure to thrive.
At follow-up at the age of 6 years and 10 months, 
his height was 112.3 cm (–2.16SD) and weight was 19.4 
kg (–1.38SD); therefore, we changed the diagnosis to 
idiopathic short stature. BA was 5.6 years old. Because 
the patient’s height displayed a trend of continuous 
decline, the parents requested height intervention. 
After imaging and ultrasonic examination, he started 
rhGH therapy at a dose of 0.15 IU∙kg–1∙d–1, following 
careful considerations of the risks and benefits, as well 
as a discussion with the child’s parents about the Chiari 
malformation type I found in the brain MRI.
The check-up visits were held every 3 months. 
Through the first year of treatment, his GV was 7.6 
cm/year, 6.5 cm/year in the second year, and 6.5 cm/year 
in the third year. The progress of the patient’s body 
weight and height gain, BA, and IGF-1 before and dur-
ing rhGH treatment are shown in Table 1 and Fig. 1. 
Because the therapeutic effect on the child was lower 
than expected (the HtSDS increased by 0.96 SD in 
31 months after treatment), we suggested that the pa-
tient undergo genetic testing to further clarify the cause 
of short stature. At this time, we learned that the par-
ents had concealed the family genetic medical history 
and the patient’s uncle (mother’s brother) was short, 
with a height of 134.0 cm. The patient was examined 
by whole-genome sequencing in another hospital, and 
the result indicated that there was a splicing site muta-
tion of the TRAPPC2 gene: c.-19-2A > G. The anterior 
and lateral X-ray of the spine and pelvis showed the 
anterior edge of the vertebral body becoming pointed 
in the middle and lower thoracic, and lumbar (shown in 
Fig. 1). The pathogenicity of this site has been previously 
reported [1], combined with the clinical phenotype and 
family history of the children, confirmed as SEDT-XL. 
SEDT-XL is caused by a single gene mutation that 
plays a key role in the targeting and fusion of endoplasmic 
reticulum to Golgi transport vesicles [2]. Affected males 
exhibit linear growth deficiency beginning at around 
6~8 years old. In early childhood, skeletal dysplasia leads 
to growth deficiency, and in later childhood, the child 
develops a disproportionately short stature (upper- to 
lower-body segment ratio is usually about 0.8), along with 
barrel chest and scoliosis [3]. However, the patient had no 
other recognizable specific facial features or other local de-
formities. According to literature reports, the adult height 
of Chinese male patients was mostly less than 150 cm, and 
only 1 affected male had an adult height of 159 cm [4].
GH treatment for children with skeletal dysplasia has 
been used to improve height outcomes. To date, only 2 
patients have reported the use of GH treatment with 
childhood growth retardation. In 2003, Shaw MA, et al.[5] 
reported a patient (c.333_336delGAAT mutation in exon 
6) from a Slovak family, who started GH treatment at 10 
years, but his height did not improve. In a case review of 
a pedigree, Li Juan et al. [6] mentioned that a 9-year-old 
proband (c.267_271delAAGAC mutation in exon 5) had 
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been treated with GH for 1 year, and his height increased 
by 5.1 cm during the treatment, which was close to the 
low limit of the normal growth rate of peers. 
Herein, we report a case of an SEDT-XL patient who 
grew 18.4 cm after 31 months of GH treatment, reach-
ing the 10th percentile of the height of children of the 
same sex and age. So far, disproportionate and serious 
complications have not occurred. The parents intend to 
continue GH treatment under regular monitoring. We 
will follow the children for a long time to see if the im-
provement in height SDS sustains through adulthood.
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table 1. Anthropometric parameters, bone age, and insulin-like growth factor 1 of patient before and during rhGH treatment
Age [years and months] Height [cm] Height SD Weight [kg] Weight SD BA  [years]
IGF-1 
[ng/mL]
3 years and 10 months 97.8 –1.33 14.7 –0.93
4 years and 9 months 103.4 –1.50 17.9 –0.24
6 years and 1 month 109.0 –1.91 18.1 –1.27 5.4 years *
6 years and 10 months 
(start of rhGH treatment) 112.3 –2.16 19.4 –1.38 5.6 years 143
7 years and 1 month 114.7 –2.00 21.0 –1.04
7 years and 4 months 117.2 –1.82 22.7 –0.71 6.5 years 289
7 years and 8 months 118.9 –1.78 24.0 –0.58 666
7 years and 11 months 120.5 –1.71 23.5 –0.89 217
8 years and 2 months 122.4 –1.58 27.3 –0.13 7.8 years 387
8 years and 6 months 124.6 –1.52 26.5 –0.54
8 years and 11 months 127.0 –1.41 29.5 –0.15 8.6 years 450
9 years and 2 months 128.8 –1.27 31.5 0.09
9 years and 5 months 130.7 –1.20 31.0 –0.17
*the result was in the medical records of the patient, but because it was the result of another hospital, we did not see the original X-ray film; SD — standard deviation 
score; BA — bone age; IGF-1 — insulin-like growth factor 1
Figure 1. X-ray radiographs of the patient. a. Spine anteroposterior 
film. B. Anterior edge of the vertebral body becomes pointed in the 
middle and lower thoracic, and lumbar seen on the lateral view, 
and narrow intervertebral disc spaces. C. BA was 5.6 years at the 
age of 6 years and 10 months; D. BA was 6.5 years at the age of 7 
years and 4 months; e. BA was 7.8 years at the age of 8 years and 
2 months; F. BA was 8.6 years at the age of 8 years and 11 months
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